{"prompt": "['period) at any time during study participation.', 'The investigator must immediately notify CTEP in the event of a confirmed', 'pregnancy in a participant in the study.', 'Termination of the study by sponsor.', 'The drug manufacturer(s) no longer manufacture the drugs.', '4.4', 'Duration of Follow Up', 'All participants will be followed for 12 weeks after removal from protocol treatment or', 'until death, whichever occurs first. Participants who discontinue study participation will be', 'able to continue prescribed chemotherapy off protocol per institutional standard of care.', 'AMC-S007 (Version 2.0) 20MAR2018', '20', 'NCI Version Date 20MAR2018']['5.0', 'DOSING DELAYS/DOSE MODIFICATIONS', 'Except as noted below, if an adverse event requiring a delay in chemotherapy does not', 'recover to the level required for continued chemotherapy treatment within 3 weeks of the', 'scheduled date of the next cycle (i.e., within 42 days after the start of the previous cycle),', 'chemotherapy should be discontinued.', 'In any case in which the dose of prescribed chemotherapy is reduced due to toxicity, any', 'future dosing (for that cycle and all subsequent cycles) should be at the reduced dose unless', 'otherwise noted.', '5.1', 'Dose Modifications for BV', 'Table 5-A: Dose Modifications for BV - Nausea', 'Event Name', 'Nausea', 'Grade of Event', 'Management/Next Dose', 'VI Grade 1', 'No change in next dose.', 'Grade 2', 'No change in next dose. Increase supportive antiemetics.', 'Grade 3/4', 'Delay start of cycle until < Grade 2. Increase supportive', 'antiemetics.', '*Participants requiring a delay of \">2 weeks should go off protocol therapy.', 'Participants requiring > two dose reductions should go off protocol therapy.', 'Recommended management: antiemetics.', 'Table 5-B: Dose Modifications for BV - Vomiting', 'Event Name', 'Vomiting', 'Grade of Event', 'Management/Next Dose', 'VI Grade 1', 'No change in next dose', 'Grade 2', 'No change in next dose. Increase supportive antiemetics', 'Grade 3', 'Delay start of cycle* until < Grade 2. Increase supportive', 'antiemetics', 'Grade 4', 'Off protocol therapy', '*Participants requiring a delay of > 2 weeks should go off protocol therapy.', 'Participants requiring > two dose reductions should go off protocol therapy.', 'Recommended management: antiemetics.', 'AMC-S007 (Version 2.0) 20MAR2018', '21', 'NCI Version Date 20MAR2018']['Table 5-C: Dose Modifications for BV - Anemia', 'Event Name', 'Anemia', 'Grade of Event', 'Management/Next Dose', 'Grade 1', 'No change in next dose', '(LLN - 10g/dL)', 'Grade 2', 'No change in next dose', '(< 10 - 8.0 g/dL)', 'Red blood cell transfusion is recommended to increase the', 'hemoglobin level to > 8.0 g/dL. Chemotherapy can', 'continue for hemoglobin < 8.0 - 6.5 /dL.', 'For hemoglobin < 6.5 g/dL, chemotherapy should be held', 'Grade 3 - 4', 'and the participant transfused with red blood cells until the', '(< 8 g/dL)', 'hemoglobin level has returned to > 8.0 g/dL. Study', 'medication may then be resumed at full dose.', 'If hemoglobin <6.5 g/dL recurs after resumption of', 'chemotherapy, the participant should again be transfused', 'as above. Chemotherapy may then be resumed as follows:', '25% reduction in the dose of both drugs.', 'Participants requiring > two dose reductions should go off protocol therapy.', 'Table 5-D: Dose Modifications for BV - Neutropenia', 'Event Name', 'Neutropenia', 'Grade of Event', 'Management/Next Dose', 'VI Grade 1', 'No change in next dose', '(LLN-1500/mm\u00b3)', 'Grade 2', 'No change in next dose', '(< 1500-1000/mm\u00b3', 'Grade 3', 'Delay start of cycle until < Grade 3. No change in next', '(< 1000-500/mm\u00b3', 'dose. If delayed a second time, decrease bleomycin by', '25%.', '*', 'Grade 4', 'Delay start of cycle until < Grade 3. Resume but', '<500/mm\u00b3', 'decrease bleomycin dose 25%. ***', '*Participants requiring a delay of > 2 weeks should go off protocol therapy.', '\"Participants requiring > two dose reductions should go off protocol therapy.', '*** Febrile neutropenia: ANC < 0.5x109/L plus fever requiring hospitalization,', 'reduce dose to 11mg/m\u00b2 for all future BV therapy.', 'AMC-S007 (Version 2.0) 20MAR2018', '22', 'NCI Version Date 20MAR2018']\n\n###\n\n", "completion": "END"}